Sr. Financial Analyst - Newark, CA | Biospace
Get Our FREE Industry eNewsletter

Sr. Financial Analyst

Depomed, Inc.

Newark, CA
Posted Date:
Position Type:
Full time
Job Code:
Required Education:
Bachelors Degree
Areas of Expertise Desired:

Job Description

City Newark
State California [CA]
Title Sr. Financial Analyst
Job ID 905XX
Date Added 3/14/2017
Department Finance


As a member of the Financial Planning and Analysis Team, the role supports the Research and Development and Contract Manufacturing functions from a financial perspective, managing the expense budgeting, accounting, forecasting and analysis process. Represents the Company’s Finance department on external Research and Development collaborations. The role also covers certain ad hoc corporate level financial support and analysis

•Manage annual Budgeting and quarterly Forecasting process for seven R&D and Contract Manufacturing departments, including budget and forecast template preparation, assist the departments with completion of the forecasts, PowerPoint slides for quarterly business review, and any additional analysis needed to aid R&D forecasting needs.
•Responsible for month end activities relating to R&D / CM departments, including monthly accrual preparation, set-up and maintenance of accrual tracking for larger contracts, actual vs. budget/forecast reports, etc.
•Work closely with Clinical team on clinical trial expenses, including monthly meeting with the Clinical team and quarterly call with CROs. Manage Clinical Trial accounting and execute controls around Clinical Trial Expenses.
•Provide Contract manufacturing team with insight on expense and invoice tracking for CMO validation projects.
•Develop and maintain the long-range Clinical Trial expense forecast and scenarios.
•Finance representative on Clinical Trial Collaborations, responsible for financial coordination and reporting with license and collaborative partners on project expense forecasts and month-end accruals.
•Finance representative on Post-Marketing Requirement and REMS Consortiums, responsible for project expense forecasts and month-end accruals.
•Work with internal and external auditors to provide supporting documentation/analyses related with R&D/CM departments.
•Various Ad Hoc Corporate financial support and analysis.

•Develop strong cross-functional working relationships with R&D/Contract Manufacturing departmental heads and employees
•Interaction with executives


•Bachelor’s Degree
•3-5+ years of experience in Finance or Accounting

•Strong Communication Skills
•Strong Multi-tasking
•Advanced Excel
•Strong Mathematical skills
•Experience with Accounting Software
•Experience Adaptive Insights a plus
•Experience with Microsoft Dynamics a plus

•Decisions & Judgment
•Ownership & Initiative
•Adaptability & Change Readiness
•Teamwork & Collaboration

•Sitting 80%
•Standing/ walking: 10%
•Repetitive motion: 50%
•Visual Requirements: 100%

About Us

Depomed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. Founded in 1995, Depomed has successfully executed on strategy of acquiring, integrating and growing differentiated therapeutic products and building each into a strong market presence. The result is a broad portfolio of pain and neurology specialty pharmaceuticals currently comprised of five FDA-approved products. These include Gralise® for the management of Postherpetic Neuralgia (PHN), Cambia® for the acute treatment of migraine attacks, Zipsor® for the relief of mild to moderate acute pain, Lazanda® for the management of breakthrough pain in cancer patients and our most recent addition, the company’s flagship asset, the NUCYNTA® franchise.

Acquired in April 2015 and re-launched in June 2015, the NUCYNTA franchise includes NUCYNTA® ER for the extended management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) and NUCYNTA® for immediate management of moderate to severe acute pain in adults.

Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. The company’s Acuform technology is currently being used in four marketed drugs, including Gralise.

Depomed’s successful execution on strategy and has resulted in solid product revenue growth over the past three years. Located in Newark, California in the East Bay of San Francisco, Depomed is listed on the NASDAQ market under the ticker DEPO and employs approximately 500 people, of which approximately 350 are part of the Commercial organization.